Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks - Yahoo Finance

* Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks  Yahoo Finance
* ResMed Stock Is Sinking. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.  Barron's
* Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company  Investors | Eli Lilly and Company
* Amid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod  FiercePharma
* Weight-Loss Drug Zepbound Offers a New Way to Treat Sleep Apnea  The New York Times


http://dlvr.it/T8jY6g